The effect of curcumin on serum copper, zinc, and zinc/copper ratio in patients with β-thalassemia intermedia: a randomized double-blind clinical trial

Saeidnia, Mohammadreza; Nowrouzi-Sohrabi, Peyman; Erfani, Mehran; Fazeli, Pooria; Tamaddon, Gholamhossein; Karimi, Mehran

doi:10.1007/s00277-021-04397-z

Cited by 5 publications

(3 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Curcumin provides a protective effect on copper toxicity in thalassemia intermedia patients. It also shows that curcumin regulates zinc homeostasis which can be useful as a treatment method for patients with thalassemia intermedia, and especially in patients with zinc deficiency or low serum zinc/copper ratio [43].…”

Section: Efficacy Of Curcuminmentioning

confidence: 99%

Role of Curcumin in Beta Thalassemia: A Review

Keerthana

Sinduja

Priyadharshini

2021

JPRI

View full text Add to dashboard Cite

Beta-thalassemia is an inherited blood disorder characterized by defective beta chains of hemoglobin which often lead to the development of anemia. These patients require periodic blood transfusions to compensate for anemia. However, these transfusions often lead to complications such as iron overload. This abnormal hemoglobin can lead to anemia and cause other medical problems. Curcumin which is a polyphenol has anti-inflammatory properties and also can increase the number of antioxidants in the body. The main aim of the study is to determine the efficiency of curcumin in the treatment of β-Thalassemia. The administration of curcumin in the treatment of β-Thalassemia has aided to be beneficial. Curcumin also exhibited hepatoprotective properties as serum bilirubin decreased in the β-Thalassemia patients. Supplementation of curcumin is seen to improve insulin resistance, lipid profile, and systemic inflammation by reducing HOMA-IR, TG, TG/HDL ratio, and hs-CRP levels. Curcumin when used in the treatment for β-Thalassemia showed low or no side effects. It has powerful anti-inflammatory effects and acts as a potent antioxidant where it can neutralize the free radicals due to its chemical structure.

show abstract

Section: Efficacy Of Curcuminmentioning

confidence: 99%

Role of Curcumin in Beta Thalassemia: A Review

Keerthana

Sinduja

Priyadharshini

2021

JPRI

View full text Add to dashboard Cite

show abstract

“…In another study, 500 mg/day curcumin reduced levels of HOMA-IR, TG, TG to HDL-cholesterol ratio, and hs-CRP levels compared to both placebo and baseline values in patients with β-thalassemia major ( n = 68) . In another randomized double-blind clinical trial, curcumin (500 mg thrice a day) reduced copper, ferritin, BMI, TG, and HDL levels and increased serum zinc levels and the zinc-to-copper ratio in β-thalassemia . In a permuted block randomized study, curcuminoids (500 and 1000 mg/day) reduced the hypercoagulability marker D-dimer, NTBI, ROS, MDA, D-dimer, hs-CRP, TNF-α, TGF-β1, IFN-γ, IL-1β, IL-6, IL-8, serum iron, and transferrin saturation in β-thalassemia .…”

Section: Clinical Trials Of Turmeric and Curcuminmentioning

confidence: 99%

“…497 In another randomized double-blind clinical trial, curcumin (500 mg thrice a day) reduced copper, ferritin, BMI, TG, and HDL levels and increased serum zinc levels and the zinc-to-copper ratio in βthalassemia. 498 In a permuted block randomized study, curcuminoids (500 and 1000 mg/day) reduced the hypercoagulability marker D-dimer, NTBI, ROS, MDA, D-dimer, hs-CRP, TNF-α, TGF-β1, IFN-γ, IL-1β, IL-6, IL-8, serum iron, and transferrin saturation in β-thalassemia. 499 Recently, a randomized, double-blind study showed that curcumin supplementation reduced serum levels of iron, ferritin, and transferrin when compared to placebo in patients with βthalassemia intermedia.…”

Section: Turmeric and Curcumin In Inheritedmentioning

confidence: 99%

Role of Turmeric and Curcumin in Prevention and Treatment of Chronic Diseases: Lessons Learned from Clinical Trials

Kunnumakkara

Hegde

Dey

et al. 2023

ACS Pharmacol. Transl. Sci.

View full text Add to dashboard Cite

Turmeric (Curcuma longa) has been used for thousands of years for the prevention and treatment of various chronic diseases. Curcumin is just one of >200 ingredients in turmeric. Almost 7000 scientific papers on turmeric and almost 20,000 on curcumin have been published in PubMed. Scientific reports based on cell culture or animal studies are often not reproducible in humans. Therefore, human clinical trials are the best indicators for the prevention and treatment of a disease using a given agent/drug. Herein, we conducted an extensive literature survey on PubMed and Scopus following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. The keywords "turmeric and clinical trials" and "curcumin and clinical trials" were considered for data mining. A total of 148 references were found to be relevant for the key term "turmeric and clinical trials", of which 70 were common in both PubMed and Scopus, 44 were unique to PubMed, and 34 were unique to Scopus. Similarly, for the search term "curcumin and clinical trials", 440 references were found to be relevant, of which 70 were unique to PubMed, 110 were unique to Scopus, and 260 were common to both databases. These studies show that the golden spice has enormous health and medicinal benefits for humans. This Review will extract and summarize the lessons learned about turmeric and curcumin in the prevention and treatment of chronic diseases based on clinical trials.

show abstract